KLK5 Antibody, FITC conjugated

Code CSB-PA897100LC01HU
Size US$166
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) KLK5 Polyclonal antibody
Uniprot No.
Target Names
KLK5
Alternative Names
HK5 antibody; Kallikrein 5 antibody; Kallikrein L2 antibody; Kallikrein like 2 antibody; Kallikrein like protein 2 antibody; Kallikrein related peptidase 5 antibody; Kallikrein-5 antibody; Kallikrein-like protein 2 antibody; Kallikrein5 antibody; KLK 5 antibody; KLK L2 antibody; KLK-L2 antibody; KLK5 antibody; KLK5_HUMAN antibody; KLKL 2 antibody; KLKL2 antibody; SCTE antibody; Stratum corneum tryptic enzyme antibody; UNQ570/PRO1132 antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Kallikrein-5 protein (23-293AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
FITC
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form
Liquid
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
May be involved in desquamation.
Gene References into Functions
  1. persistently upregulated KLK5 resulted in atopic dermatitis-like skin architecture and secretion of atopic dermatitis-related cytokines from keratinocytes in a PAR2 independent manner PMID: 28238749
  2. It may be considered that circulating kallikrein 5 is down-regulated in chronic spontaneous urticaria patients, however its potential role and the possible underlying mechanism are unknown. PMID: 28685545
  3. Thus, these findings point to the involvement of KLK5 in the proteolytic activation and spread of seasonal influenza viruses in humans. PMID: 28615200
  4. The results of the present study indicated that the mRNA and protein expression levels of KLK5 were significantly upregulated in CRC tissues and sera, and were associated with an advanced tumor stage. PMID: 27430713
  5. the expression level of hK5 in tumor stromal cells is a promising biomarker for poor prognosis in TNBC. PMID: 26345898
  6. This report demonstrates that concurrent loss of KLK5 and KLK7 associates with a poor clinical outcome in Oral Squamous-Cell Carcinoma and could therefore serve as prognostic marker in this disease. PMID: 26022646
  7. Low KLK5 expression is associated with breast cancer. PMID: 24158494
  8. KLK5 is an important contributor to the Netherton syndrome proteolytic cascade. PMID: 24534191
  9. Data indicate that the KLK5 SNP rs268908 was associated with an increased risk of prostate cancer. PMID: 21741862
  10. Kallikrein 5 and kallikrein 12 cleave human influenza hemagglutinins and activate thrombolytic zymogens. PMID: 23612974
  11. KLK5 is required for biochemical processing of profilaggrin in human skin. PMID: 23629652
  12. the inhibition and binding of different SPINK9 variants towards KLK5, KLK7, KLK8 and KLK14 PMID: 22505519
  13. Loss of KLK5 is associated with ovarian cancer. PMID: 22102857
  14. Increased serum and ascitic fluid KLK5 levels are associated with poor patient outcome, thus underlining the importance of KLK5 as a biomarker for early detection as well as for disease management in ovarian cancer. PMID: 21273346
  15. Significant co-expression of KLKs 5 and 7 was observed in the same cancer samples. Increased KLK5 expression was a statistically significant independent prognostic factor for DFS and OS of patients PMID: 21868565
  16. KLK5 may promote metastatic dissemination of OSCC by promoting loss of junctional integrity through cleavage of desmoglein 1. PMID: 21163944
  17. expression and activity of KLK are under fine control and can be distinctly influenced by variables such as differentiation, calcium, vitamin D, and retinoic acid PMID: 20090765
  18. expression in prostate cancer negatively correlated with cancer aggressiveness PMID: 11948967
  19. We found significantly lower expression of KLK5 in testicular tumors than in normal testicular tissue. PMID: 12385949
  20. High expression of KLK5 transcript with a short 5'-untranslated region is associated with ovarian cancer PMID: 12738725
  21. has trypsin-like substrate specificity and forms complexes with protease inhibitors in serum and ascites fluid from ovarian cancer patients PMID: 12890555
  22. scte induced degradation of three corneodesmosomal components: corneodesmosin, desmocollin 1 and desmoglein 1 PMID: 15140227
  23. may be part of a protease cascade in the stratum corneum, and that the observed pH effects may have physiological relevance PMID: 15654974
  24. hK5 may be implicated in tumor progression, particularly in invasion and angiogenesis PMID: 15713679
  25. variability in KLK5 and KLK7 gene expression might be involved in lung tumorigenesis PMID: 15766562
  26. hK5 is able to internally cleave insulin-like growth factor-binding proteins 1, 2, 3, 4, and 5, but not 6, suggesting that it might be involved in prostate cancer progression through growth factor regulation PMID: 16517595
  27. in majority of patients with Netherton syndrome, Dsg1 & Dsc1 were reduced in living layers of epidermis; SCTE-like & SCCE-like activities were increased, suggesting these proteases participate in premature degradation of corneodesmosomal cadherins PMID: 16628198
  28. KLK5 and KLK7 were shown to control activation of CAP18 and also influence further processing to smaller peptides with alternate biological activity; the balance of proteolytic activity at an epithelial interface will control innate immune defense PMID: 17012259
  29. KLK5 may participate in epidermal desquamation through cleavage of desmoglein 1 and regulation by lympho-epithelial Kazal-type-related inhibitor (LEKTI). PMID: 17158887
  30. A target of gene amplification, which may play a crucial role in promoting cancer-cell invasion in bladder tumor. PMID: 17459052
  31. KLK5 and KLK14, but neither KLK7 nor KLK8, induced PAR2 signalling. PMID: 17625593
  32. Dada shoe that the His96-99-57 triad is responsible for the Zn2+-mediated inhibition of hK5 catalysis. PMID: 17881000
  33. predominant localisation of KLK5 and KLK7 in acinar cells of the exocrine pancreas; KLK5 and KLK7 generate transcripts in pancreas variant from those in skin or ovary PMID: 18163887
  34. KLK4 and KLK5 activate pro-HGFA. PMID: 18221492
  35. the KLK region was subject to copy number imbalances or involved in unbalanced translocations and were associated with increased protein expression of KLKs 5, 6, 7, 8, 9, 10 and 11 in ovarian cancer cells PMID: 19383346
  36. Parallel underexpression of KLK5 and KLK7 mRNA in breast malignancies is reported. PMID: 19453546
  37. KLK5 is a potential new biomarker to be used in combination with other biomarkers for ovarian cancer detection. PMID: 19820362

Show More

Hide All

Subcellular Location
Secreted.
Protein Families
Peptidase S1 family, Kallikrein subfamily
Tissue Specificity
Expressed in skin, breast, brain and testis. Expressed at the stratum granulosum of palmar skin.
Database Links

HGNC: 6366

OMIM: 605643

KEGG: hsa:25818

STRING: 9606.ENSP00000337733

UniGene: Hs.50915

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*